Press Release

NAPLES, Fla., – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announces it has surpassed 10,000 total shoulder arthroplasty (TSA) procedures as it closes $20 million in equity and venture debt financing with funding partners RC Capital,…

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D. as chief strategy officer of the organization, effective immediately. “The board and I are excited to have an executive with Dr. Ables’ experience and leadership join our team…

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed seasoned medical device leader Mark Quick as chief financial officer of the organization, effective immediately. Quick joins Catalyst with nearly two decades of medical device experience. He was most recently at Orthofix Medical Inc.…

Internationally known shoulder surgeon Theodore Blaine, MD, performed first series of procedures Theodore Blaine, MD, has completed the first series of total shoulder arthroplasty procedures using the Catalyst Stemmed CSR TSA fully convertible system with an ellipsoid humeral head. (Photo: Business Wire) NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (Catalyst), a medical device…

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head. This is the market’s first stemmed arthroplasty system featuring…

Visit booth #2408 for product demonstrations of the Archer™ Shoulder Systems NAPLES, Fla., March 22, 2022 – Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will be at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting, March 23-25, 2022, in Chicago. At booth #2408,…

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.